Literature DB >> 9066749

Multiple operations in patients with bony metastases and a prolonged course of disease.

U Helwig1.   

Abstract

A retrospective study of 19 patients suffering from bone metastases with a survival time of more than 24 months, and having undergone at least three operations, is reported. Fourteen patients had to have multiple surgery because of local recurrences after internal fixation supported by bone cement (n = 12) or tumour resection alone (n = 2). Only five of 19 patients had several operations because of multiple-site bony metastases without any unnecessary surgery as a result of failed local tumour control with recurrences. A complete and extralesional resection of solitary bone metastases with a potentially poor response to radiotherapy, such as hypernephroma, could help to avoid additional surgery in patients with a shortened life expectancy.

Entities:  

Mesh:

Year:  1997        PMID: 9066749     DOI: 10.1016/s0748-7983(97)80144-8

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  [Internal fixation of meta- and diaphyseal intercalary bone defects after tumour resection with intramedullary nailing and porous polymethylmetacrylate (PMMA) spacer].

Authors:  A Biewener; J Meyer; C Rentsch; R Grass; K P Günther; H Zwipp; S Rammelt
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

2.  Quality of life measurement in bone metastases: A literature review.

Authors:  Sukirtha Tharmalingam; Edward Chow; Kristin Harris; Amanda Hird; Emily Sinclair
Journal:  J Pain Res       Date:  2008-10-01       Impact factor: 3.133

3.  Mid and long-term overall survival after carcinologic resections of thyroid cancer bone metastases.

Authors:  Henri Fragnaud; Jean-Camille Mattei; Louis-Romée Le Nail; Mỹ-Vân Nguyễn; Thomas Schubert; Anthony Griffin; Jay Wunder; David Biau; François Gouin; Paul Bonnevialle; Gualter Vaz; Mickael Ropars; Vincent Crenn
Journal:  Front Surg       Date:  2022-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.